HOME >> BIOLOGY >> NEWS
Developer of new method for treating bone defects wins WPI Entrepreneurship Award

WORCESTER, Mass. June 20, 2007 The founder of a biomedical company that has developed a polymer technology for treating bone defects has won the 2007 Kalenian Award from Worcester Polytechnic Institute (WPI). Albert G. Prescott II, a 1990 WPI graduate and president of Crescent Innovations in Worcester, will receive $25,000 to help further development and commercialization of the novel technology.

The Kalenian Award was established in 2006 by Alba Kalenian in memory of her late husband, inventor Aram Kalenian '33. Its purpose is to encourage innovation and entrepreneurship among WPI students, faculty, and alumni by providing seed funds to advance their ideas. Alba Kalenian says her husband believed "the highest and best use of a WPI education is to invent, and patent, then create an invention-based business and employ."

This award funds a single viable invention each year. Proposals are reviewed by Paul Kalenian, son of Aram and Alba, and McRae Banks, head of WPI's Department of Management and director of the university's Collaborative for Entrepreneurship and Innovation. The winner is selected based on the novelty of the invention, as well as its commercial potential and the likelihood of its success. The seed funds are designed to help recipient move their inventions toward commercialization.

Crescent Innovations Inc. was founded in 2000 to develop products to treat TMJ (temporomandibular joint) disorders, degenerative joint disease, bone disease, fractures, and more, using proprietary polymer technology. These state-of-the-art polymers are used to treat chronic and acute pain, along with controlled release/drug delivery products. The company has received a Phase I SBIR grant from the National Institutes of Health, and has worked with Fortune 500 companies.

"I cannot emphasize enough how important this award is to us at Crescent Innovations," Prescott says. "The technology we are developing to treat bone defects will ulti
'"/>

Contact: Michael Dorsey
mwdorsey@wpi.edu
508-831-5609
Worcester Polytechnic Institute
20-Jun-2007


Page: 1 2

Related biology news :

1. Cost-effective method for gene silencing is featured in Cold Spring Harbor Protocols
2. A new method of adult stem cell growth efficacious in treatment of disorders of the cornea
3. Purdue-IU researchers explore new method for early disease diagnosis
4. Sequencing method yields fuller picture
5. New imaging method clarifies nutrient cycle
6. Researchers discover method for identifying how cancer evades the immune system
7. Bioinformatics-related methods are featured in Cold Spring Harbor Protocols
8. New method for reading DNA sheds light on basis of cell identity
9. Nanoparticles hitchhike on red blood cells: a potential new method for drug delivery
10. Rutgers, Penn researchers capture research dollars to improve prostate cancer diagnostic methods
11. New screening method to help find better biofuel crops

Post Your Comments:
(Date:5/23/2013)... Pacific Northwest National Laboratory honored more than ... of intellectual property at PNNL,s annual Intellectual Property ... The Department of Energy national laboratory named materials ... his work developing battery materials that can store ... electrical grid, and reduce the time it takes ...
(Date:5/23/2013)... 284 million tons of cargo, transit the Panama Canal each ... the Panama Canal Authority. Each time a ship passes through, ... Gatun Lake, which is also a source of water for ... However, the advent of very large "super" cargo ships, now ... demanded change. The Panama Canal is being expanded to create ...
(Date:5/23/2013)... Health at Emory University, along with partners at ... $4 million grant over four years to establish ... Exposome Research Center: Understanding Lifetime Exposures). The grant ... the United States. , The HERCULES Center ... Health Sciences (NIEHS) of the National Institutes of ...
Breaking Biology News(10 mins):PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
(Date:5/23/2013)... 2013 Graphite Metallizing Corporation announces ... mounted in stainless steel pillow blocks. This series ... with the application and installation versatility of pillow ... work exceptionally well when submerged in water, ... such as acids, alkalies, hydrocarbons, black liquor, and ...
(Date:5/23/2013)... The maker community is a contemporary group ... focus on learning practical skills while applying them creatively ... their ideas to life via crowdfunding. A subgroup within ... projects using biology. Glowing Plant has worked for months ... glow with bioluminescence genes, and has now pursued crowdfunding ...
(Date:5/23/2013)... Virobay, Inc. today announced that their development ... important milestone, as Virobay has now initiated a Phase ... S inhibitor.   The first Phase 1 ... designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics ... "The initiation of this Phase 1 trial with ...
(Date:5/23/2013)... 23, 2013 Northwest Biotherapeutics (NASDAQ: ... ® personalized immune therapies for solid tumor cancers, ... this year,s American Society Of Clinical Oncology (ASCO) meeting ... leadership role in immune therapy.  (Logo: ... is the pre-eminent conference focused on clinical treatment of ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
Cached News: